ATE545629T1 - Verfahren zur herstellung von atorvastatin- calcium in amorpher form - Google Patents

Verfahren zur herstellung von atorvastatin- calcium in amorpher form

Info

Publication number
ATE545629T1
ATE545629T1 AT04798913T AT04798913T ATE545629T1 AT E545629 T1 ATE545629 T1 AT E545629T1 AT 04798913 T AT04798913 T AT 04798913T AT 04798913 T AT04798913 T AT 04798913T AT E545629 T1 ATE545629 T1 AT E545629T1
Authority
AT
Austria
Prior art keywords
atorvastatin calcium
amorphic form
producing atorvastatin
producing
amorphic
Prior art date
Application number
AT04798913T
Other languages
English (en)
Inventor
Yatendra Kumar
S M Kumar
Swargam Sathyanarayana
Original Assignee
Ranbaxy Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Lab Ltd filed Critical Ranbaxy Lab Ltd
Application granted granted Critical
Publication of ATE545629T1 publication Critical patent/ATE545629T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT04798913T 2004-03-17 2004-11-19 Verfahren zur herstellung von atorvastatin- calcium in amorpher form ATE545629T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN491DE2004 2004-03-17
PCT/IB2004/003789 WO2005092852A1 (en) 2004-03-17 2004-11-19 Process for the production of atorvastatin calcium in amorphous form

Publications (1)

Publication Number Publication Date
ATE545629T1 true ATE545629T1 (de) 2012-03-15

Family

ID=33516010

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04798913T ATE545629T1 (de) 2004-03-17 2004-11-19 Verfahren zur herstellung von atorvastatin- calcium in amorpher form

Country Status (17)

Country Link
US (1) US7994343B2 (de)
EP (3) EP1577297A1 (de)
CN (2) CN1942439B (de)
AR (1) AR048271A1 (de)
AT (1) ATE545629T1 (de)
AU (2) AU2004317570B2 (de)
CA (3) CA2560252C (de)
CY (1) CY1112583T1 (de)
DK (1) DK1727795T3 (de)
ES (1) ES2381473T3 (de)
FI (1) FI120344B (de)
MY (1) MY147435A (de)
NO (1) NO330092B1 (de)
PL (1) PL1727795T3 (de)
PT (1) PT1727795E (de)
SI (1) SI1727795T1 (de)
WO (1) WO2005092852A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1727795E (pt) * 2004-03-17 2012-04-11 Ranbaxy Lab Ltd Processo para a produção de atorvastatina cálcica na forma amorfa
HUE029911T2 (en) * 2004-07-16 2017-04-28 Lek Pharmaceuticals Products of atorvastatin calcium oxidative degradation
JP2008510798A (ja) * 2004-08-27 2008-04-10 バイオコン・リミテッド 非晶質アトルバスタチンカルシウムのための方法
GB2424880A (en) * 2005-04-06 2006-10-11 Generics Crystalline forms of atorvastatin sodium, processes for their preparation and their use in inhibiting HMG-CoA reductase
GB0613566D0 (en) * 2006-07-07 2006-08-16 Arrow Int Ltd Crystalline sodium atorvastatin
GB0613567D0 (en) * 2006-07-07 2006-08-16 Arrow Int Ltd Crystalline sodium atorvastatin
CN101268047B (zh) 2005-08-15 2012-11-07 箭锋国际有限公司 结晶和无定形阿托伐他汀钠
EP1928823B1 (de) 2005-08-15 2014-10-08 Arrow International Limited Verfahren zur Herstellung eines kristallinen ATORVASTATIN Natrium Salzes
ES2270722B1 (es) * 2005-09-15 2008-03-01 Ercros Industrial, S.A. Procedimiento para la obtencion de atorvastatina calcica amorfa.
GB0523637D0 (en) * 2005-11-21 2005-12-28 Avecia Pharmaceuticals Ltd Process and compounds
WO2007099552A2 (en) * 2006-03-02 2007-09-07 Matrix Labaratories Ltd Novel crystalline form of atovastatin hemi-magnesium
SI22255A (sl) * 2006-04-14 2007-10-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Novi polimorfi statinovih soli in njihova uporabav farmacevtskih formulacijah
CN101205209B (zh) * 2007-12-25 2010-06-02 浙江新东港药业股份有限公司 一种阿伐他汀中间体的精制方法
EP2075246A1 (de) * 2007-12-27 2009-07-01 M. J. Institute of Research Verfahren zur Herstellung einer amorphen Form von Atorvastatin-Hemicalcium-Salz
CN101468963B (zh) * 2007-12-28 2012-09-19 石药集团中奇制药技术（石家庄）有限公司 一种无定形阿伐他汀钙的制备方法
KR100850558B1 (ko) * 2008-01-02 2008-08-06 조동옥 아토르바스타틴의 효율적인 제조방법
CN101560177B (zh) * 2008-04-16 2012-10-03 北京万全阳光医学技术有限公司 一种阿托伐他汀钙的制备方法
CN101429195B (zh) * 2008-11-03 2010-12-15 华东师范大学 一种高纯度阿托伐他汀重要合成中间体的制备方法
US8115015B2 (en) 2009-01-26 2012-02-14 Cadila Healthcare Limited Process for the preparation of amorphous atorvastatin calcium
EP2560951B1 (de) * 2010-04-19 2016-05-25 DSM Sinochem Pharmaceuticals Netherlands B.V. Herstellung von atorvastatin mit geringen etherunreinheiten
CN102127060B (zh) * 2010-12-17 2013-12-04 蚌埠丰原医药科技发展有限公司 一种阿托伐他汀钙中间体的制备方法
CN102070504A (zh) * 2010-12-23 2011-05-25 蚌埠丰原医药科技发展有限公司 阿托伐他汀钠的制备方法
CN102070505B (zh) * 2011-01-28 2012-01-11 海南美大制药有限公司 阿托伐他汀钙化合物及其新制法
CN103483238B (zh) * 2013-08-20 2014-12-31 蚌埠丰原医药科技发展有限公司 阿托伐他汀钙三水合物的制备方法
CN104945300B (zh) * 2015-06-17 2017-05-10 北京嘉林药业股份有限公司 一种ⅰ型阿托伐他汀钙的纯化方法
WO2017060885A1 (en) * 2015-10-09 2017-04-13 Laurus Labs Private Limited An improved process for preparation of atorvastatin or pharmaceutically acceptable salts thereof
CN106478591B (zh) * 2016-09-30 2018-11-13 北京嘉林药业股份有限公司 一种阿托伐他汀缩合物中间体的拆分方法
CN106432033B (zh) * 2016-10-21 2018-07-27 江苏阿尔法药业有限公司 一种无定形阿托伐他汀钙的制备方法
CN108033899B (zh) * 2017-12-06 2020-04-10 浙江科技学院 一种(r)-6-氰基-5-羟基-3-羰基己酸叔丁酯的制备方法
CN109280024A (zh) * 2018-10-09 2019-01-29 河南师范大学 一种高纯度阿托伐他汀叔丁酯的制备方法
CN109232355A (zh) * 2018-10-09 2019-01-18 河南师范大学 一种有效去除阿托伐他汀钙粗品中杂质阿托伐他汀缩合物的方法
CN110563628B (zh) * 2019-08-26 2022-04-05 北京嘉林药业股份有限公司 一种双釜制备高纯度和单分散i晶型阿托伐他汀钙的结晶方法
CN110776451B (zh) * 2020-01-02 2020-05-22 湖南迪诺制药股份有限公司 一种i晶型阿托伐他汀钙的制备方法
CN113695307B (zh) * 2020-05-20 2022-12-02 天津嘉林科医有限公司 一种盛放阿托伐他汀钙的玻璃器皿的清洗方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5003080A (en) 1988-02-22 1991-03-26 Warner-Lambert Company Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
US5149837A (en) 1988-02-22 1992-09-22 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5097045A (en) 1989-02-01 1992-03-17 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5124482A (en) 1988-02-22 1992-06-23 Warner-Lambert Company Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis
US5216174A (en) 1988-02-22 1993-06-01 Warner-Lambert Co. Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5245047A (en) 1988-02-22 1993-09-14 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5248793A (en) 1990-10-17 1993-09-28 Warner-Lambert Company Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5103024A (en) 1990-10-17 1992-04-07 Warner-Lambert Company Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5155251A (en) 1991-10-11 1992-10-13 Warner-Lambert Company Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate
JP3254219B2 (ja) 1993-01-19 2002-02-04 ワーナー−ランバート・コンパニー 安定な経口用のｃｉ−９８１製剤およびその製法
US5298627A (en) 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
HRP960312B1 (en) * 1995-07-17 2001-10-31 Warner Lambert Co NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1)
PL193479B1 (pl) 1995-07-17 2007-02-28 Warner Lambert Co Formy krystaliczne hydratu atorwastatyny, kompozycja farmaceutyczna zawierająca formę krystaliczną I hydratu atorwastatyny oraz jej zastosowanie
IN191236B (de) 1999-05-25 2003-10-11 Ranbaxy Lab Ltd
HU226640B1 (en) 1999-10-18 2009-05-28 Egis Gyogyszergyar Nyilvanosan Process for producing amorphous atorvastatin calcium salt
US6646133B1 (en) * 2000-10-17 2003-11-11 Egis Gyogyszergyar Rt. Process for the preparation of amorphous atorvastatin calcium
SI20425A (sl) 1999-12-10 2001-06-30 LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. Priprava amorfnega atorvastatina
ATE260101T1 (de) 2000-06-09 2004-03-15 Lek Tovarna Farmacevtskih Stabilisierte pharmazeutisch wirksame zubereitung und diese enthaltende arzneizusammensetzung
CN1535139A (zh) 2000-11-03 2004-10-06 ������ҩ��ҵ���޹�˾ 阿伐他丁半钙形式ⅶ
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
AU2002246675A1 (en) 2000-12-18 2002-07-30 Merck And Co., Inc. Thrombin inhibitors
PL365312A1 (en) 2000-12-27 2004-12-27 Teva Pharmaceutical Industries Ltd Crystalline forms of atorvastatin
WO2002057228A1 (en) 2001-01-17 2002-07-25 Biocon India Limited Atorvastatin calcium
SI20814A (sl) 2001-01-23 2002-08-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Priprava amorfnega atorvastatina
IN190564B (de) * 2001-04-11 2003-08-09 Cadila Heathcare Ltd
KR100609371B1 (ko) 2001-06-29 2006-08-08 워너-램버트 캄파니 엘엘씨 Ｒ-(ｒ*,ｒ*)-2-(4-플루오로페닐)-베타,델타-디히드록시-5-(1-메틸에틸)-3-페닐-4-페닐아미노)카르보닐-1ｈ-피롤-1-헵탄산 칼슘염 (2:1) (아토르바스타틴)의 결정질 형태
PL368647A1 (en) 2001-07-30 2005-04-04 Dr.Reddy's Laboratories Ltd. Crystalline forms vi and vii of atorvastatin calcium
CA2456095C (en) 2001-08-31 2010-05-11 Morepen Laboratories Ltd. An improved process for the preparation of amorphous atorvastatin calcium salt (2:1)
CZ296967B6 (cs) * 2002-02-01 2006-08-16 Zentiva, A.S. Zpusob výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu)
BR0215644A (pt) 2002-03-18 2004-12-21 Biocon Ltd Inibidores de redutase de hmg-coa amorfos do tamanho de partìcula desejado
AU2002356423A1 (en) 2002-05-28 2003-12-12 Cadila Healthcare Limited Process for the preparation of amorphous atorvastatin calcium
SI21302A (sl) 2002-10-11 2004-04-30 LEK farmacevtska dru�ba d.d. Stabiliziran farmacevtski izdelek z amorfno aktivno učinkovino
HU227041B1 (en) 2003-03-24 2010-05-28 Richter Gedeon Nyrt Process for the synthesis of amorphous atorvastatin calcium
PT1727795E (pt) * 2004-03-17 2012-04-11 Ranbaxy Lab Ltd Processo para a produção de atorvastatina cálcica na forma amorfa
CA2579997A1 (en) 2004-09-28 2006-04-06 Teva Pharmaceutical Industries Ltd. Process for preparing forms of atorvastatin calcium substantially free of impurities

Also Published As

Publication number Publication date
AU2004317570A1 (en) 2005-10-06
AU2010249166B2 (en) 2012-02-09
FI120344B (fi) 2009-09-30
EP1727795A1 (de) 2006-12-06
ES2381473T3 (es) 2012-05-28
SI1727795T1 (sl) 2012-05-31
EP1727795B1 (de) 2012-02-15
MY147435A (en) 2012-12-14
US7994343B2 (en) 2011-08-09
PT1727795E (pt) 2012-04-11
EP1659110A1 (de) 2006-05-24
FI20041489A0 (fi) 2004-11-19
PL1727795T3 (pl) 2012-06-29
CY1112583T1 (el) 2016-02-10
CN1942439A (zh) 2007-04-04
NO330092B1 (no) 2011-02-14
EP1577297A1 (de) 2005-09-21
FI20041489A (fi) 2006-07-20
CA2627940A1 (en) 2005-10-06
CA2560252C (en) 2009-08-04
DK1727795T3 (da) 2012-04-16
CN1946688A (zh) 2007-04-11
US20100197941A1 (en) 2010-08-05
WO2005092852A1 (en) 2005-10-06
NO20045037D0 (no) 2004-11-19
AU2010249166A1 (en) 2010-12-23
CA2560252A1 (en) 2005-10-06
CN1942439B (zh) 2011-12-21
AR048271A1 (es) 2006-04-12
NO20045037L (no) 2005-09-19
CA2666359A1 (en) 2005-10-06
AU2004317570B2 (en) 2011-01-06

Similar Documents

Publication Publication Date Title
ATE545629T1 (de) Verfahren zur herstellung von atorvastatin- calcium in amorpher form
DE602005019848D1 (de) Verfahren zur herstellung von tad- getrocknetem ti
ATE408609T1 (de) Verfahren zur herstellung von n-phenylpyrazol-1- carboxamiden
ATE408604T1 (de) Verfahren zur herstellung von 1-alkyl-3- phenyluracilen
ATE440888T1 (de) Verfahren zur herstellung von glatiramer
ATE399761T1 (de) Verfahren zur herstellung von dinitrilen
ATE430480T1 (de) Verfahren zur herstellung von nährmittelzusammensetzungen
ATE516816T1 (de) Verfahren zur herstellung von impfstoffen
ATE476411T1 (de) Verfahren zur herstellung von 3-pentennitril
ATE489015T1 (de) Verfahren zur herstellung von verschlüssen
DE602006015090D1 (de) Verfahren zur herstellung von gezielt durchlässigen laminaten
ATE457969T1 (de) Verfahren zur herstellung von aloe-emodin
DE602005023438D1 (de) Verfahren zur herstellung von polyestern
ATE444303T1 (de) Verfahren zur herstellung von ferrisuccinylcasein
ATE488508T1 (de) Verfahren zur herstellung von irbesartan und zwischenprodukte davon
ATE406372T1 (de) Verfahren zur herstellung von 3-o-geschützten morphinonen und 3-o-geschützten morphinondienolcarboxylaten
DE602005017099D1 (de) Verfahren zur Herstellung von amorphem Cefuroximaxetil
DE502005001997D1 (de) Verfahren zur herstellung von silanisierten kohlenstoff-nanoröhren
ATE549314T1 (de) Verfahren zur herstellung von 4-aminochinazolinen
ATE427040T1 (de) Verfahren zur herstellung von nahrungsmitteln und so hergestelltes nahrungsmittel
DE502005003871D1 (de) Verfahren zur herstellung von elementhalogeniden
DE50308650D1 (de) Verfahren zur herstellung von cellulosecarbamatformkörpern
ATE417839T1 (de) Verfahren zur herstellung von amorolfin
ATE392404T1 (de) Verfahren zur herstellung von methanol
ATE521596T1 (de) Verfahren zur herstellung von pyrimidinverbindungen